Skip to main content
Erschienen in: AIDS and Behavior 2/2017

28.06.2016 | Original Paper

Antiretroviral Therapy Interruption Among HIV Postive People Who Use Drugs in a Setting with a Community-Wide HIV Treatment-as-Prevention Initiative

verfasst von: Ryan McNeil, Thomas Kerr, Bill Coleman, Lisa Maher, M. J. Milloy, Will Small

Erschienen in: AIDS and Behavior | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

HIV Treatment as Prevention (TasP) initiatives promote antiretroviral therapy (ART) access and optimal adherence (≥95 %) to produce viral suppression among people living with HIV (PLHIV) and prevent the onward transmission of HIV. ART treatment interruptions are common among PLHIV who use drugs and undermine the effectiveness of TasP. Semi-structured interviews were conducted with 39 PLHIV who use drugs who had experienced treatment ART interruptions in a setting with a community-wide TasP initiative (Vancouver, Canada) to examine influences on these outcomes. While study participants attributed ART interruptions to “treatment fatigue,” our analysis revealed individual, social, and structural influences on these events, including: (1) prior adverse ART-related experiences among those with long-term treatment histories; (2) experiences of social isolation; and, (3) breakdowns in the continuity of HIV care following disruptive events (e.g., eviction, incarceration). Findings reconceptualise ‘treatment fatigue’ by focusing attention on its underlying mechanisms, while demonstrating the need for comprehensive structural reforms and targeted interventions to optimize TasP among drug-using PLHIV.
Literatur
1.
Zurück zum Zitat Montaner JSG, Lima VD, Harrigan PR, Lourenço L, Yip B, Nosyk B, et al. Expansion of HAART coverage is associated with sustained decreases in HIV/AIDS morbidity, mortality and HIV transmission: the “HIV Treatment as Prevention” experience in a Canadian setting. PLoS One. 2014;9(2):e87872.CrossRefPubMedPubMedCentral Montaner JSG, Lima VD, Harrigan PR, Lourenço L, Yip B, Nosyk B, et al. Expansion of HAART coverage is associated with sustained decreases in HIV/AIDS morbidity, mortality and HIV transmission: the “HIV Treatment as Prevention” experience in a Canadian setting. PLoS One. 2014;9(2):e87872.CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Lima VD, Lourenço L, Yip B, Hogg RS, Phillips P, Montaner JSG. AIDS incidence and AIDS-related mortality in British Columbia, Canada, between 1981 and 2013: a retrospective study. Lancet HIV. 2015;2(3):e92–7.CrossRefPubMedPubMedCentral Lima VD, Lourenço L, Yip B, Hogg RS, Phillips P, Montaner JSG. AIDS incidence and AIDS-related mortality in British Columbia, Canada, between 1981 and 2013: a retrospective study. Lancet HIV. 2015;2(3):e92–7.CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Duncan KC, Chan KJ, Chiu CG, Montaner JSG, Coldman AJ, Cescon A, et al. HAART slows progression to anal cancer in HIV-infected MSM. AIDS. 2015;29(3):305–11.CrossRefPubMed Duncan KC, Chan KJ, Chiu CG, Montaner JSG, Coldman AJ, Cescon A, et al. HAART slows progression to anal cancer in HIV-infected MSM. AIDS. 2015;29(3):305–11.CrossRefPubMed
4.
Zurück zum Zitat Wood E, Hogg RS, Yip B, Harrigan PR, O’Shaughnessy MV. Montaner JSG. Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4 + cell count is 0.200 to 0.350 × 109 cells/L. Ann Intern Med. 2003;139(10):810–6.CrossRefPubMed Wood E, Hogg RS, Yip B, Harrigan PR, O’Shaughnessy MV. Montaner JSG. Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4 + cell count is 0.200 to 0.350 × 109 cells/L. Ann Intern Med. 2003;139(10):810–6.CrossRefPubMed
5.
Zurück zum Zitat Montaner JSG, Lima VD, Barrios R, Yip B, Wood E, Kerr T, et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet. 2010;376(9740):532–9.CrossRefPubMedPubMedCentral Montaner JSG, Lima VD, Barrios R, Yip B, Wood E, Kerr T, et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet. 2010;376(9740):532–9.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Tanser F, Bärnighausen T, Grapsa E, Zaidi J, Newell M-L. High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal. S Afr Sci. 2013;339(6122):966–71. Tanser F, Bärnighausen T, Grapsa E, Zaidi J, Newell M-L. High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal. S Afr Sci. 2013;339(6122):966–71.
7.
Zurück zum Zitat Bangsberg DR. Less than 95 % adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis. 2006;43(7):939–41.CrossRefPubMed Bangsberg DR. Less than 95 % adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis. 2006;43(7):939–41.CrossRefPubMed
8.
Zurück zum Zitat Yehia BR, Fleishman JA, Metlay JP, Moore RD, Gebo KA. Sustained viral suppression in HIV-infected patients receiving antiretroviral therapy. JAMA. 2012;308(4):339–42.CrossRefPubMedPubMedCentral Yehia BR, Fleishman JA, Metlay JP, Moore RD, Gebo KA. Sustained viral suppression in HIV-infected patients receiving antiretroviral therapy. JAMA. 2012;308(4):339–42.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505.CrossRefPubMedPubMedCentral Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Wood E, Kerr T, Marshall BD, Li K, Zhang R, Hogg RS, et al. Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. BMJ. 2009;338:b1649.CrossRefPubMedPubMedCentral Wood E, Kerr T, Marshall BD, Li K, Zhang R, Hogg RS, et al. Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. BMJ. 2009;338:b1649.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat De Cock KM, Fowler MG, Mercier E, de Vincenzi I, Saba J, Hoff E, et al. Prevention of mother-to-child HIV transmission in resource-poor countries: translating research into policy and practice. JAMA. 2000;283(9):1175–82.CrossRefPubMed De Cock KM, Fowler MG, Mercier E, de Vincenzi I, Saba J, Hoff E, et al. Prevention of mother-to-child HIV transmission in resource-poor countries: translating research into policy and practice. JAMA. 2000;283(9):1175–82.CrossRefPubMed
12.
Zurück zum Zitat Montaner JSG, Hogg R, Wood E, Kerr T, Tyndall M, Levy AR, et al. The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet. 2006;368(9534):531–6.CrossRefPubMed Montaner JSG, Hogg R, Wood E, Kerr T, Tyndall M, Levy AR, et al. The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet. 2006;368(9534):531–6.CrossRefPubMed
13.
14.
Zurück zum Zitat Hull MW, Wu Z, Montaner JSG. Optimizing the engagement of care cascade: a critical step to maximize the impact of HIV treatment as prevention. Curr Opin HIV AIDS. 2012;7(6):579–86.CrossRefPubMed Hull MW, Wu Z, Montaner JSG. Optimizing the engagement of care cascade: a critical step to maximize the impact of HIV treatment as prevention. Curr Opin HIV AIDS. 2012;7(6):579–86.CrossRefPubMed
15.
16.
Zurück zum Zitat Thompson MA, Aberg JA, Hoy JF, Telenti A, Benson C, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society–USA panel. JAMA. 2012;308(4):387–402.CrossRefPubMed Thompson MA, Aberg JA, Hoy JF, Telenti A, Benson C, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society–USA panel. JAMA. 2012;308(4):387–402.CrossRefPubMed
17.
Zurück zum Zitat World Health Organization. Antiretroviral treatment as prevention (TASP) of HIV and TB: programmatic update. Geneva: World Health Organization; 2012. World Health Organization. Antiretroviral treatment as prevention (TASP) of HIV and TB: programmatic update. Geneva: World Health Organization; 2012.
18.
Zurück zum Zitat Joint United Nations Programme on HIV/AIDS. 90-90-90: an ambitious treatment target to help end the AIDS epidemic. Geneva: UNAIDS; 2014. Joint United Nations Programme on HIV/AIDS. 90-90-90: an ambitious treatment target to help end the AIDS epidemic. Geneva: UNAIDS; 2014.
19.
Zurück zum Zitat Nosyk B, Lourenço L, Min JE, Shopin D, Lima VD, Montaner JSG, et al. Characterizing retention in HAART as a recurrent event process: insights into ‘cascade churn’. AIDS. 2015;29(13):1681–9.CrossRefPubMedPubMedCentral Nosyk B, Lourenço L, Min JE, Shopin D, Lima VD, Montaner JSG, et al. Characterizing retention in HAART as a recurrent event process: insights into ‘cascade churn’. AIDS. 2015;29(13):1681–9.CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Hamlyn E, Ewings FM, Porter K, Cooper DA, Tambussi G, Schechter M, et al. Plasma HIV viral rebound following protocol-indicated cessation of ART commenced in primary and chronic HIV infection. PLoS One. 2012;7:e43754.CrossRefPubMedPubMedCentral Hamlyn E, Ewings FM, Porter K, Cooper DA, Tambussi G, Schechter M, et al. Plasma HIV viral rebound following protocol-indicated cessation of ART commenced in primary and chronic HIV infection. PLoS One. 2012;7:e43754.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Lima VD, Bangsberg DR, Harrigan PR, Deeks SG, Yip B, Hogg RS, et al. Risk of viral failure declines with duration of suppression on HAART, irrespective of adherence level. J Acquir Immune Defic Syndr. 2010;55(4):460.CrossRefPubMedPubMedCentral Lima VD, Bangsberg DR, Harrigan PR, Deeks SG, Yip B, Hogg RS, et al. Risk of viral failure declines with duration of suppression on HAART, irrespective of adherence level. J Acquir Immune Defic Syndr. 2010;55(4):460.CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Wainberg MA, Zaharatos GJ, Brenner BG. Development of antiretroviral drug resistance. N Engl J Med. 2011;365(7):637–46.CrossRefPubMed Wainberg MA, Zaharatos GJ, Brenner BG. Development of antiretroviral drug resistance. N Engl J Med. 2011;365(7):637–46.CrossRefPubMed
23.
Zurück zum Zitat Friedland GH, Williams A. Attaining higher goals in HIV treatment: the central importance of adherence. AIDS. 1999;13:S61–72.PubMed Friedland GH, Williams A. Attaining higher goals in HIV treatment: the central importance of adherence. AIDS. 1999;13:S61–72.PubMed
24.
Zurück zum Zitat Milloy M-J, Montaner J, Wood E. Barriers to HIV treatment among people who use injection drugs: implications for ‘treatment as prevention’. Curr Opin HIV AIDS. 2012;7(4):332–8.CrossRefPubMed Milloy M-J, Montaner J, Wood E. Barriers to HIV treatment among people who use injection drugs: implications for ‘treatment as prevention’. Curr Opin HIV AIDS. 2012;7(4):332–8.CrossRefPubMed
25.
Zurück zum Zitat Wood E, Milloy MJ, Montaner JSG. HIV treatment as prevention among injection drug users. Curr Opin HIV AIDS. 2012;7(2):151–6.CrossRefPubMed Wood E, Milloy MJ, Montaner JSG. HIV treatment as prevention among injection drug users. Curr Opin HIV AIDS. 2012;7(2):151–6.CrossRefPubMed
26.
Zurück zum Zitat Krüsi A, Wood E, Montaner J, Kerr T. Social and structural determinants of HAART access and adherence among injection drug users. Int J Drug Policy. 2010;21(1):4–9.CrossRefPubMed Krüsi A, Wood E, Montaner J, Kerr T. Social and structural determinants of HAART access and adherence among injection drug users. Int J Drug Policy. 2010;21(1):4–9.CrossRefPubMed
27.
Zurück zum Zitat Kerr T, Marshall A, Walsh J, Palepu A, Tyndall M, Montaner J, et al. Determinants of HAART discontinuation among injection drug users. AIDS Care. 2005;17(5):539–49.CrossRefPubMed Kerr T, Marshall A, Walsh J, Palepu A, Tyndall M, Montaner J, et al. Determinants of HAART discontinuation among injection drug users. AIDS Care. 2005;17(5):539–49.CrossRefPubMed
28.
Zurück zum Zitat Hughes AJ, Mattson CL, Scheer S, Beer L, Skarbinski J. Discontinuation of antiretroviral therapy among adults receiving HIV care in the United States. J Acquir Immune Defic Syndr. 2014;66(1):80–9.CrossRefPubMedPubMedCentral Hughes AJ, Mattson CL, Scheer S, Beer L, Skarbinski J. Discontinuation of antiretroviral therapy among adults receiving HIV care in the United States. J Acquir Immune Defic Syndr. 2014;66(1):80–9.CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Kempf M-C, Pisu M, Dumcheva A, Westfall AO, Kilby JM, Saag MS. Gender differences in discontinuation of antiretroviral treatment regimens. J Acquir Immune Defic Syndr. 2009;52(3):336–41.CrossRefPubMed Kempf M-C, Pisu M, Dumcheva A, Westfall AO, Kilby JM, Saag MS. Gender differences in discontinuation of antiretroviral treatment regimens. J Acquir Immune Defic Syndr. 2009;52(3):336–41.CrossRefPubMed
30.
Zurück zum Zitat Samji H, Chen Y, Salters K, Montaner JSG, Hogg RS. Correlates of Unstructured Antiretroviral Treatment Interruption in a cohort of HIV-Positive Individuals in British Columbia. AIDS Behav. 2014;18(11):2240–8.CrossRefPubMedPubMedCentral Samji H, Chen Y, Salters K, Montaner JSG, Hogg RS. Correlates of Unstructured Antiretroviral Treatment Interruption in a cohort of HIV-Positive Individuals in British Columbia. AIDS Behav. 2014;18(11):2240–8.CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat McNeil R, Kerr T, Anderson S, Maher L, Keewatin C, Milloy MJ, et al. Negotiating structural vulnerability following regulatory changes to a provincial methadone program in vancouver, canada: a qualitative study. Soc Sci Med. 2015;133:168–76.CrossRefPubMedPubMedCentral McNeil R, Kerr T, Anderson S, Maher L, Keewatin C, Milloy MJ, et al. Negotiating structural vulnerability following regulatory changes to a provincial methadone program in vancouver, canada: a qualitative study. Soc Sci Med. 2015;133:168–76.CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Quesada J, Hart LK, Bourgois P. Structural vulnerability and health: latino migrant laborers in the United States. Med Anthropol. 2011;30(4):339–62.CrossRefPubMedPubMedCentral Quesada J, Hart LK, Bourgois P. Structural vulnerability and health: latino migrant laborers in the United States. Med Anthropol. 2011;30(4):339–62.CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Joseph B, Kerr T, Puskas CM, Montaner J, Wood E, Milloy MJ. Factors linked to transitions in adherence to antiretroviral therapy among HIV-infected illicit drug users in a Canadian setting. AIDS Care. In press. Joseph B, Kerr T, Puskas CM, Montaner J, Wood E, Milloy MJ. Factors linked to transitions in adherence to antiretroviral therapy among HIV-infected illicit drug users in a Canadian setting. AIDS Care. In press.
34.
Zurück zum Zitat Milloy MJ, Kerr T, Bangsberg DR, Buxton J, Parashar S, Guillemi S, et al. Homelessness as a structural barrier to effective antiretroviral therapy among HIV-seropositive illicit drug users in a Canadian setting. AIDS Patient Care STDs. 2012;26(1):60–7.CrossRefPubMedPubMedCentral Milloy MJ, Kerr T, Bangsberg DR, Buxton J, Parashar S, Guillemi S, et al. Homelessness as a structural barrier to effective antiretroviral therapy among HIV-seropositive illicit drug users in a Canadian setting. AIDS Patient Care STDs. 2012;26(1):60–7.CrossRefPubMedPubMedCentral
35.
Zurück zum Zitat Claborn KR, Meier E, Miller MB, Leffingwell TR. A systematic review of treatment fatigue among HIV-infected patients prescribed antiretroviral therapy. Psychol Health Med. 2015;20(3):255–65.CrossRefPubMed Claborn KR, Meier E, Miller MB, Leffingwell TR. A systematic review of treatment fatigue among HIV-infected patients prescribed antiretroviral therapy. Psychol Health Med. 2015;20(3):255–65.CrossRefPubMed
36.
Zurück zum Zitat Samji H, Taha TE, Moore D, Burchell AN, Cescon A, Cooper C, et al. Predictors of unstructured antiretroviral treatment interruption and resumption among HIV-positive individuals in Canada. HIV Med. 2015;16(2):76–87.CrossRefPubMed Samji H, Taha TE, Moore D, Burchell AN, Cescon A, Cooper C, et al. Predictors of unstructured antiretroviral treatment interruption and resumption among HIV-positive individuals in Canada. HIV Med. 2015;16(2):76–87.CrossRefPubMed
37.
Zurück zum Zitat Hill S, Kavookjian J, Qian J, Chung A, Vandewaa J. Effects of pill burden on discontinuation of the initial HAART regimen in minority female patients prescribed 1 pill/day versus any other pill burden. AIDS Care. 2014;26(5):595–601.CrossRefPubMed Hill S, Kavookjian J, Qian J, Chung A, Vandewaa J. Effects of pill burden on discontinuation of the initial HAART regimen in minority female patients prescribed 1 pill/day versus any other pill burden. AIDS Care. 2014;26(5):595–601.CrossRefPubMed
38.
Zurück zum Zitat Wood E, Hogg RS, Lima VD, Kerr T, Yip B, Marshall BDL, et al. Highly active antiretroviral therapy and survival in HIV-infected injection drug users. JAMA. 2008;300(5):550–4.CrossRefPubMed Wood E, Hogg RS, Lima VD, Kerr T, Yip B, Marshall BDL, et al. Highly active antiretroviral therapy and survival in HIV-infected injection drug users. JAMA. 2008;300(5):550–4.CrossRefPubMed
39.
Zurück zum Zitat Lopez AM, Bourgois P, Wenger LD, Lorvick J, Martinez AN, Kral AH. Interdisciplinary mixed methods research with structurally vulnerable populations: case studies of injection drug users in San Francisco. Int J Drug Policy. 2013;24(2):101–9.CrossRefPubMedPubMedCentral Lopez AM, Bourgois P, Wenger LD, Lorvick J, Martinez AN, Kral AH. Interdisciplinary mixed methods research with structurally vulnerable populations: case studies of injection drug users in San Francisco. Int J Drug Policy. 2013;24(2):101–9.CrossRefPubMedPubMedCentral
40.
Zurück zum Zitat Moore D, Dray A, Green R, Hudson SL, Jenkinson R, Siokou C, et al. Extending drug ethno-epidemiology using agent-based modelling. Addiction. 2009;104(12):1991–7.CrossRefPubMed Moore D, Dray A, Green R, Hudson SL, Jenkinson R, Siokou C, et al. Extending drug ethno-epidemiology using agent-based modelling. Addiction. 2009;104(12):1991–7.CrossRefPubMed
41.
Zurück zum Zitat Krüsi A, Milloy MJ, Kerr T, Zhang R, Guillemi S, Hogg R, et al. Ongoing drug use and outcomes from highly active antiretroviral therapy among injection drug users in a Canadian setting. Antivir Ther. 2010;15(5):789.CrossRefPubMed Krüsi A, Milloy MJ, Kerr T, Zhang R, Guillemi S, Hogg R, et al. Ongoing drug use and outcomes from highly active antiretroviral therapy among injection drug users in a Canadian setting. Antivir Ther. 2010;15(5):789.CrossRefPubMed
42.
Zurück zum Zitat McNeil R, Dilley LB, Guirguis-Younger M, Hwang SW, Small W. Impact of supervised drug consumption services on access to and engagement with care at a palliative and supportive care facility for people living with HIV/AIDS: a qualitative study. J Int AIDS Soc. 2014;17(1):18855.CrossRefPubMedPubMedCentral McNeil R, Dilley LB, Guirguis-Younger M, Hwang SW, Small W. Impact of supervised drug consumption services on access to and engagement with care at a palliative and supportive care facility for people living with HIV/AIDS: a qualitative study. J Int AIDS Soc. 2014;17(1):18855.CrossRefPubMedPubMedCentral
43.
Zurück zum Zitat Small W, Wood E, Betteridge G, Montaner J, Kerr T. The impact of incarceration upon adherence to HIV treatment among HIV-positive injection drug users: a qualitative study. AIDS Care. 2009;21(6):708–14.CrossRefPubMed Small W, Wood E, Betteridge G, Montaner J, Kerr T. The impact of incarceration upon adherence to HIV treatment among HIV-positive injection drug users: a qualitative study. AIDS Care. 2009;21(6):708–14.CrossRefPubMed
44.
Zurück zum Zitat Milloy MJ, Kerr T, Buxton J, Rhodes T, Guillemi S, Hogg R, et al. Dose-response effect of incarceration events on nonadherence to HIV antiretroviral therapy among injection drug users. J Infect Dis. 2011;203(9):1215–21.CrossRefPubMedPubMedCentral Milloy MJ, Kerr T, Buxton J, Rhodes T, Guillemi S, Hogg R, et al. Dose-response effect of incarceration events on nonadherence to HIV antiretroviral therapy among injection drug users. J Infect Dis. 2011;203(9):1215–21.CrossRefPubMedPubMedCentral
45.
Zurück zum Zitat Werb D, Milloy MJ, Kerr T, Zhang R, Montaner J, Wood E. Injection drug use and HIV antiretroviral therapy discontinuation in a Canadian setting. AIDS Behav. 2013;17(1):68–73.CrossRefPubMedPubMedCentral Werb D, Milloy MJ, Kerr T, Zhang R, Montaner J, Wood E. Injection drug use and HIV antiretroviral therapy discontinuation in a Canadian setting. AIDS Behav. 2013;17(1):68–73.CrossRefPubMedPubMedCentral
46.
Zurück zum Zitat Bradley EH, Curry LA, Devers KJ. Qualitative data analysis for health services research: developing taxonomy, themes, and theory. Health Serv Res. 2007;42(4):1758–72.CrossRefPubMedPubMedCentral Bradley EH, Curry LA, Devers KJ. Qualitative data analysis for health services research: developing taxonomy, themes, and theory. Health Serv Res. 2007;42(4):1758–72.CrossRefPubMedPubMedCentral
47.
Zurück zum Zitat Strathdee SA, Patrick DM, Currie SL, Cornelisse PGA, Rekart ML, Montaner JSG, et al. Needle exchange is not enough: lessons from the Vancouver injecting drug use study. AIDS. 1997;11(8):F60–5.CrossRef Strathdee SA, Patrick DM, Currie SL, Cornelisse PGA, Rekart ML, Montaner JSG, et al. Needle exchange is not enough: lessons from the Vancouver injecting drug use study. AIDS. 1997;11(8):F60–5.CrossRef
48.
Zurück zum Zitat Yuan Y, L’Italien G, Mukherjee J, Iloeje UH. Determinants of discontinuation of initial highly active antiretroviral therapy regimens in a US HIV-infected patient cohort. HIV Med. 2006;7(3):156–62.CrossRefPubMed Yuan Y, L’Italien G, Mukherjee J, Iloeje UH. Determinants of discontinuation of initial highly active antiretroviral therapy regimens in a US HIV-infected patient cohort. HIV Med. 2006;7(3):156–62.CrossRefPubMed
49.
Zurück zum Zitat Ammassari A, Murri R, Pezzotti P, Trotta MP, Ravasio L, De Longis P, et al. Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr. 2001;28(5):445–9.CrossRefPubMed Ammassari A, Murri R, Pezzotti P, Trotta MP, Ravasio L, De Longis P, et al. Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr. 2001;28(5):445–9.CrossRefPubMed
50.
Zurück zum Zitat Lawrence J, Mayers DL, Hullsiek KH, Collins G, Abrams DI, Reisler RB, et al. Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus. N Engl J Med. 2003;349(9):837–46.CrossRefPubMed Lawrence J, Mayers DL, Hullsiek KH, Collins G, Abrams DI, Reisler RB, et al. Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus. N Engl J Med. 2003;349(9):837–46.CrossRefPubMed
51.
Zurück zum Zitat Milloy MJ, Montaner JSG, Wood E. Incarceration of people living with HIV/AIDS: implications for treatment-as-prevention. Curr HIV AIDS Rep. 2014;11(3):308–16.CrossRef Milloy MJ, Montaner JSG, Wood E. Incarceration of people living with HIV/AIDS: implications for treatment-as-prevention. Curr HIV AIDS Rep. 2014;11(3):308–16.CrossRef
52.
Zurück zum Zitat Milloy MJ, Marshall BDL, Montaner J, Wood E. Housing status and the health of people living with HIV/AIDS. Curr HIV AIDS Rep. 2012;9(4):364–74.CrossRef Milloy MJ, Marshall BDL, Montaner J, Wood E. Housing status and the health of people living with HIV/AIDS. Curr HIV AIDS Rep. 2012;9(4):364–74.CrossRef
53.
Zurück zum Zitat Wood E, Werb D, Kazatchkine M, Kerr T, Hankins C, Gorna R, et al. Vienna declaration: a call for evidence-based drug policies. Lancet. 2010;376(9738):310–2.CrossRefPubMed Wood E, Werb D, Kazatchkine M, Kerr T, Hankins C, Gorna R, et al. Vienna declaration: a call for evidence-based drug policies. Lancet. 2010;376(9738):310–2.CrossRefPubMed
54.
Zurück zum Zitat Wolfe D, Cohen J. Human rights and HIV prevention, treatment, and care for people who inject drugs: key principles and research needs. J Acquir Immune Defic Syndr. 2010;55:S56–62.CrossRefPubMed Wolfe D, Cohen J. Human rights and HIV prevention, treatment, and care for people who inject drugs: key principles and research needs. J Acquir Immune Defic Syndr. 2010;55:S56–62.CrossRefPubMed
Metadaten
Titel
Antiretroviral Therapy Interruption Among HIV Postive People Who Use Drugs in a Setting with a Community-Wide HIV Treatment-as-Prevention Initiative
verfasst von
Ryan McNeil
Thomas Kerr
Bill Coleman
Lisa Maher
M. J. Milloy
Will Small
Publikationsdatum
28.06.2016
Verlag
Springer US
Erschienen in
AIDS and Behavior / Ausgabe 2/2017
Print ISSN: 1090-7165
Elektronische ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-016-1470-2

Weitere Artikel der Ausgabe 2/2017

AIDS and Behavior 2/2017 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.